Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX-Reference-Cited by-同舟云学术

Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX

Published:2011-09 Issue:9 Volume:22 Page:1981-1987
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Aebi S.,Sun Z.,Braun D.,Price K.N.,Castiglione-Gertsch M.,Rabaglio M.,Gelber R.D.,Crivellari D.,Lindtner J.,Snyder R.,Karlsson P.,Simoncini E.,Gusterson B.A.,Viale G.,Regan M.M.,Coates A.S.,Goldhirsch A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/22/9/1981/13785341/mdq754.pdf

Reference24 articles.

1. International web-based consultation on priorities for translational breast cancer research;Dowsett;Breast Cancer Res,2007

2. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer;Paik;J Clin Oncol,2006

3. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27;Bear;J Clin Oncol,2006

4. Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials;Conforti;Ann Oncol,2007

5. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial;von Minckwitz;J Natl Cancer Inst,2008

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of anti-cancer drug synergy based on cross-matching network and cancer molecular subtypes;Computers in Biology and Medicine;2024-06

2. Sex steroid hormones and DNA repair regulation: Implications on cancer treatment responses;The Journal of Steroid Biochemistry and Molecular Biology;2023-03

3. Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer;Expert Review of Anticancer Therapy;2023-01-02

4. EVALUATION OF KI-67 AS INDEPENDENT RISK FACTOR AND ITS ROLE IN THE INCIDENCE OF LOCAL RECURRENCE/DISTANT METASTASIS IN LUMINAL A AND LUMINAL B (HER2 NEGATIVE) BREAST CANCER: A RETROSPECTIVE ANALYSIS FROM A SINGLE CANCER CENTER;WORLD CANCER RES J;2023

5. The Nitrogen Mustards;Pharmacological Reviews;2022-06-16